New York, USA – June 29, 2022 – Antibody-based immunotherapies are considered the next-generation strategies and approaches for many diseases in the field of drug discovery. As an innovatory CRO company engaged in antibody development for decades, Creative Biolabs announces its attendance at the 10th Antibody Industrial Symposium 2022 (AIS2022), an international congress for scientists, physicians, industrials, and policymakers to communicate advancements about therapeutic antibodies and present related comprehensive antibody development solutions throughout this 2-day meeting.
“Thank the AIS2022 for providing a platform for networking and presenting our efforts in drug discovery during the difficult COVID-19 period,” said the representative of Creative Biolabs. “Our showcase products and solutions for therapeutic antibodies at this year’s conference include antibody engineering technologies and strategies to develop monoclonal antibody biosimilars. Actually, we have even more comprehensive offerings to share at the AIS2022.”
An expansion of Creative Biolabs’ antibody product portfolio for the AIS 2022demonstration:
* Antibody-drug Conjugate (ADC)
As a new class of highly potent targeted therapeutics for cancer treatment, ADC has become one of the most promising engineered therapeutic antibody products. Along with free HPLC/ELISA/TFC-MS/MS analysis services for drug and pharmacokinetics research, Creative Biolabs integrates with comprehensive designing, discovery, expression, and purification services for antibody-drug conjugates.
* Monoclonal Antibody Biosimilars
Creative Biolabs demonstrates a list of common monoclonal antibody biosimilars that are similar to the approved biologics but at a reduced production cost. For these complex and large molecules, especially the most promising antibody-based proteins, Creative Biolabs prepares a wide range of therapeutic antibodies to enhance the development of biosimilars targeting different diseases.
“We are excited to exchange ideas with industry counterparts as well as prospective customers at the 10th Antibody Industrial Symposium 2022 in France and anticipate collaboration sparks on related antibody-based immunotherapy research and development projects. Let’s see how we can help in the development of antibody, cell and gene therapies, and other biopharmaceutical fields.” The representative adds.
Learn more therapeutic antibody solutions featured for the 10th Antibody Industrial Symposium 2022 and business partnering opportunities with Creative Biolabs at https://www.creativebiolabs.net.
Creative Biolabs is a CRO with a mission of delivering quality preclinical research solutions to the pharmaceutical, biotech, and med-tech industries. The company is relentlessly focused on carrying forward research on antibody-based immunotherapy, cell therapy, gene therapy, and other biopharmaceuticals research and development, as well as promoting innovative approaches and new trend technologies in developing innovative therapeutic antibodies until clinical success.